HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study

Table 4 Cox Regression of Factors Associated with Mortality, DMMS WAVE 2 patients with HIVAN only

	One-Year Unadjusted Survival Factor Present	One-Year Unadjusted Survival Factor Absent	P Value	AHR	95% CI
African American Race* (vs. all other races)	54%	40%	0.05	0.20	0.04, 0.99
	Two-Year Unadjusted Survival	Two-Year Unadjusted Survival
Antiretroviral therapy (yes/No)	15%	39%	0.21	1.92	0.69, 5.37
Multiple antiretroviral agents (yes/No)	22%	33%	0.60	0.62	0.10, 3.86
ACE inhibitors (vs. nonuse)	13%	29%	0.28	2.26	0.55, 9.31
CCB (vs. nonuse)	42%	25%	0.36	0.56	0.16, 1.96
Male (vs. female)	33%	17%	0.31	0.44	0.09, 2.16
Peritoneal Dialysis (vs. Hemodialysis)	38%	26%	0.47	0.58	0.13, 2.53

N = 36, N in final model = 30 *Because so few patients with HIVAN were not African American, only one-year survival could be compared Only factors significant in the final model are shown.

ISSN: 1471-2369